scholarly journals Long term deficiency of vitamin D in germ cell testicular cancer survivors

Oncotarget ◽  
2018 ◽  
Vol 9 (30) ◽  
pp. 21078-21085 ◽  
Author(s):  
Lucia Nappi ◽  
Margaret Ottaviano ◽  
Pasquale Rescigno ◽  
Ladan Fazli ◽  
Martin E. Gleave ◽  
...  
Keyword(s):  
Vitamin D ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Germ Cell ◽  
Testicular Cancer Survivors

scholarly journals Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review

2021 ◽  
Vol 22 (10) ◽  
pp. 5145
Author(s):  
Giuseppe Schepisi ◽  
Caterina Gianni ◽  
Sara Bleve ◽  
Silvia De Padova ◽  
Cecilia Menna ◽  
...  
Keyword(s):  
Vitamin D ◽  
Testicular Cancer ◽  
Vitamin D Deficiency ◽  
Molecular Mechanisms ◽  
Hypovitaminosis D ◽  
Young Males ◽  
Report Data ◽  
Testicular Cancer Survivors ◽  
Patients Experience

Testicular cancer (TC) is the most frequent tumor in young males. In the vast majority of cases, it is a curable disease; therefore, very often patients experience a long survival, also due to their young age at diagnosis. In the last decades, the role of the vitamin D deficiency related to orchiectomy has become an increasingly debated topic. Indeed, vitamin D is essential in bone metabolism and many other metabolic pathways, so its deficiency could lead to various metabolic disorders especially in long-term TC survivors. In our article, we report data from studies that evaluated the incidence of hypovitaminosis D in TC survivors compared with cohorts of healthy peers and we discuss molecular mechanisms and clinical implications.

A study of coping in long-term testicular cancer survivors

2010 ◽  
Vol 15 (2) ◽  
pp. 146-158 ◽  
Author(s):  
Robert Rutskij ◽  
Torfinn Gaarden ◽  
Roy Bremnes ◽  
Olav Dahl ◽  
Arnstein Finset ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Testicular Cancer Survivors

Cisplatin-Induced Long-Term Hearing Impairment Is Associated With Specific Glutathione S-Transferase Genotypes in Testicular Cancer Survivors

2007 ◽  
Vol 25 (6) ◽  
pp. 708-714 ◽  
Author(s):  
Jan Oldenburg ◽  
Sigrid M. Kraggerud ◽  
Milada Cvancarova ◽  
Ragnhild A. Lothe ◽  
Sophie D. Fossa
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Hearing Impairment ◽  
Glutathione S Transferase ◽  
Functional Polymorphisms ◽  
Hearing Ability ◽  
Interindividual Variations ◽  
Glutathione S Transferases ◽  
Testicular Cancer Survivors

Purpose Cisplatin, a cornerstone of combination chemotherapy in the treatment of testicular cancer, induces hearing impairment with considerable interindividual variations. These differences might be a result of functional polymorphisms in cisplatin-detoxifying enzymes like glutathione S-transferases (GSTs). Patients and Methods We identified 173 cisplatin-treated testicular cancer survivors (TCSs) who had participated in a long-term survey that included audiometric testing and lymphocyte sampling. The hearing decibel thresholds at 4,000 Hz were categorized into leveled scales by normative decibel percentiles. Known functional polymorphisms (positive or negative) in GSTT1 and GSTM1 and codon 105 A/G (Ile/Val) in GSTP1 were analyzed by multiplex polymerase chain reaction, followed by restriction enzyme cutting, and separated by gel electrophoresis. Results The risk of having an inferior audiometric result was more than four times higher in TCSs with 105Ile/105Ile-GSTP1 or 105Val/105Ile-GSTP1 compared with 105Val/105Val-GSTP1 (odds ratio [OR] = 4.21; 95% CI, 1.99 to 8.88; P < .001 when modeled by ordinal logistic regression [OLR]). GSTM1 positivity was detrimental for hearing ability. Two combined genotypes were associated with hearing ability. The presence of pattern 1 (GSTT1 positive, GSTM1 positive, and 105Ile/105Ile-GSTP1) was associated with hearing impairment (OR = 2.76; 95% CI, 1.35 to 5.64; P = .005, OLR). TCSs with pattern 2 (GSTT1 positive, GSTM1 positive, and 105Val/105Val-GSTP1) had better hearing ability than TCSs without this pattern (OR = 5.35; 95% CI, 2.25 to 12.76; P < .001, OLR). Conclusion The presence of both alleles of 105Val-GSTP1 offered protection against cisplatin-induced hearing impairment. Two genotype patterns with good and poor protection against cisplatin-induced ototoxicity were identified.

scholarly journals Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors

2015 ◽  
Vol 26 (10) ◽  
pp. 2133-2140 ◽  
Author(s):  
M. Sprauten ◽  
H.S. Haugnes ◽  
M. Brydøy ◽  
C. Kiserud ◽  
T. Tandstad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Chronic Fatigue ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

scholarly journals Long-Term Follow Up of the Erectile Function of Testicular Cancer Survivors

2019 ◽  
Vol 10 ◽  
Author(s):  
Francesco Pallotti ◽  
Alessandra Petrozzi ◽  
Francesco Cargnelutti ◽  
Antonio Francesco Radicioni ◽  
Andrea Lenzi ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Erectile Function ◽  
Long Term Follow Up ◽  
Testicular Cancer Survivors

Long-term complications of platinum-based chemotherapy in testicular cancer survivors

2007 ◽  
Vol 24 (2) ◽  
pp. 175-181 ◽  
Author(s):  
J. H. Oh ◽  
D. D. Baum ◽  
S. Pham ◽  
M. Cox ◽  
S. T. Nguyen ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Platinum Based Chemotherapy ◽  
Testicular Cancer Survivors

scholarly journals The personality trait of neuroticism is strongly associated with long-term morbidity in testicular cancer survivors

2009 ◽  
Vol 48 (6) ◽  
pp. 842-849 ◽  
Author(s):  
Ellen Karine Grov ◽  
Sophie D. Fosså ◽  
Roy M. Bremnes ◽  
Olav Dahl ◽  
Olbjørn Klepp ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Personality Trait ◽  
Testicular Cancer Survivors

scholarly journals Treatment-related cardiovascular toxicity in long-term survivors of testicular cancer

2017 ◽  
Vol 51 (2) ◽  
pp. 221-227 ◽  
Author(s):  
Jasenka Gugic ◽  
Lorna Zadravec Zaletel ◽  
Irena Oblak
Keyword(s):  
Testicular Cancer ◽  
Cancer Survivors ◽  
Major Complication ◽  
Treatment Modalities ◽  
Cardiovascular Toxicity ◽  
Platinum Based Chemotherapy ◽  
Short Period ◽  
Modern Treatment ◽  
Testicular Cancer Survivors

Abstract Backgrounds Testicular cancer is the most common malignancy in young men. Considering increasing incidence, exceptionally high cure rate, as well as long life expectancy, assessment of long term toxicity in testicular cancer survivors is of great importance. In the last decades a major effort has been made in order to reduce toxicity of treatment, while maintaining its high effectiveness. Conclusions Actual knowledge on treatment toxicity is based on outdated treatment modalities. Hopefully, modern treatment modalities could reduce toxicity, but, there is no firm confirmation for that at the moment, as data dealing with late sequelae of modern treatment of testicular cancer are not available yet due to the short period of observation. The life-threatening cardiovascular toxicity in testicular cancer survivors is major complication of platinum-based chemotherapy, mediastinal radiotherapy and even subdiaphragmatic radiotherapy.

Sign in / Sign up

Export Citation Format

Share Document